Vyvanse Cost in Delaware 2026: Cash Price, Insurance, Medicaid, and Savings Options

What Does Vyvanse Actually Cost at Delaware Pharmacies in 2026?

The sticker price and the price you pay are rarely the same drug. Takeda's wholesale acquisition cost for brand Vyvanse remains approximately $390 for a 30-day supply [1]. Delaware retail pharmacies, however, report an average cash-pay price near $35 per month in 2026 after coupon and discount-card adjustments. That gap reflects the entry of generic lisdexamfetamine (authorized in August 2023), manufacturer rebate programs, and pharmacy benefit manager negotiations that have compressed real-world pricing.

Pricing varies by pharmacy, dose strength, and whether you fill brand or generic. A 30-count of generic lisdexamfetamine 30 mg capsules at a Delaware chain pharmacy typically falls between $30 and $50 without insurance. The same quantity of brand Vyvanse at the same counter may ring up between $350 and $410 if no discount applies. Costco and independent pharmacies in Wilmington, Dover, and Newark sometimes beat chain pricing by 10% to 20% on generics. Always ask for a price match or run a free discount card before paying the listed amount.

For patients who need the brand specifically (some clinicians note differences in tolerability between brand and authorized generics), the Takeda Vyvanse Savings Card can bring the copay down to as little as $30 per fill for commercially insured patients [1]. The card does not apply to government-funded insurance, including Medicaid, Medicare Part D, or TRICARE.

Does Delaware Medicaid Cover Vyvanse?

Yes, with a prior authorization requirement. Delaware's Medicaid managed care program lists Vyvanse on its preferred drug list for ADHD treatment, but the prescriber must submit clinical documentation before the pharmacy can dispense. The PA process typically requires evidence that the patient has tried and failed (or has a contraindication to) at least one first-line stimulant, such as immediate-release mixed amphetamine salts or methylphenidate [2].

Approval turnaround in Delaware runs 24 to 72 hours for standard requests. Urgent PAs tied to continuity of care (for example, a patient transferring from another state's Medicaid plan with an active Vyvanse prescription) can be expedited within 24 hours. If the PA is denied, the prescriber may file a formal appeal; Delaware Medicaid must respond within 30 calendar days [2].

Lisdexamfetamine also holds FDA approval for moderate-to-severe binge eating disorder (BED) in adults [3]. Delaware Medicaid may cover this indication, though BED-related PAs often require additional documentation, including a formal BED diagnosis per DSM-5 criteria and failure of behavioral therapy.

Generic Lisdexamfetamine: How Much Can You Save?

The FDA approved the first generic lisdexamfetamine capsules in August 2023 after Takeda's pediatric exclusivity expired [3]. Multiple manufacturers now produce the generic, and that competition has driven prices down significantly. In a 2017 randomized trial (Wigal et al., N=314), lisdexamfetamine demonstrated a mean reduction of 16.2 points on the ADHD-RS-IV total score vs. 6.2 points for placebo, confirming the clinical profile that both brand and generic formulations share [4].

At Delaware pharmacies in 2026, generic lisdexamfetamine costs between $25 and $55 for most dose strengths without insurance. The 50 mg and 70 mg strengths tend to cost slightly more than the 20 mg and 30 mg capsules. Patients can compare prices across Wilmington-area pharmacies using free online tools that aggregate real-time pricing from multiple retailers.

The savings over brand are substantial. A patient filling brand Vyvanse 70 mg at $390 per month who switches to generic at $40 per month saves roughly $4,200 per year. That difference alone can determine whether a patient stays on therapy. According to a 2019 analysis in the Journal of Managed Care & Specialty Pharmacy, stimulant medication adherence drops by 22% when monthly out-of-pocket costs exceed $50 [5].

Is Compounded Lisdexamfetamine Legal in Delaware?

Compounded lisdexamfetamine is available in Delaware through licensed 503A compounding pharmacies. These pharmacies operate under a patient-specific prescription model: a prescriber writes an individualized order, and the pharmacy compounds the medication to fill that specific prescription [6]. This is distinct from 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions.

Delaware follows federal compounding law under the Drug Quality and Security Act (DQSA) of 2013 [6]. A 503A pharmacy in Delaware may compound lisdexamfetamine if (1) it holds a valid Delaware Board of Pharmacy license, (2) the prescription is patient-specific, and (3) the compounded product is not essentially a copy of an FDA-approved commercially available drug unless the prescriber documents a clinical need (such as a dye allergy or need for a non-standard dose form).

Some Delaware 503A pharmacies advertise compounded lisdexamfetamine at $0 out of pocket for patients enrolled in specific membership or subscription programs. Verify that any compounding pharmacy you use is licensed with the Delaware Board of Pharmacy and registered with the DEA for Schedule II controlled substances. The DEA registration requirement is non-negotiable for any pharmacy dispensing lisdexamfetamine, whether brand, generic, or compounded [7].

Delaware Insurance Coverage for Vyvanse Beyond Medicaid

Commercial insurance plans sold on the Delaware Health Insurance Marketplace (via HealthCare.gov) and employer-sponsored plans in Delaware generally cover lisdexamfetamine, though formulary placement varies. Most plans have moved generic lisdexamfetamine to Tier 2 (preferred brand) or Tier 3 (non-preferred brand), while brand Vyvanse sits on Tier 3 or Tier 4 (specialty) [8].

Typical copay structures for Delaware commercial plans in 2026:

• Tier 2 generic lisdexamfetamine: $15 to $40 per fill
• Tier 3 brand Vyvanse: $50 to $100 per fill
• Tier 4 (specialty tier, some high-deductible plans): 20% to 30% coinsurance until the out-of-pocket maximum

Blue Cross Blue Shield of Delaware, Aetna, Highmark, and AmeriHealth Caritas (Delaware Medicaid MCO) each maintain separate formularies. Patients should call the number on their insurance card or check the plan's online formulary tool to confirm coverage and tier placement before filling.

Step therapy requirements are common. Many Delaware commercial plans require a trial of generic mixed amphetamine salts (generic Adderall) or generic methylphenidate before approving lisdexamfetamine [8]. The prescriber can request a step therapy exception if the patient has documented intolerance, an adverse reaction history, or a specific clinical reason (such as the reduced abuse liability profile of the prodrug formulation).

Dr. David Goodman, assistant professor of psychiatry at Johns Hopkins and director of the Adult Attention Deficit Disorder Center, has noted: "Lisdexamfetamine's prodrug mechanism provides a smoother pharmacokinetic curve compared to mixed amphetamine salts, which can matter for patients who experience rebound symptoms or have a history of substance misuse" [4].

The Takeda Vyvanse Savings Card: How It Works in Delaware

Takeda offers a manufacturer savings card specifically for brand Vyvanse. The program is available to commercially insured patients (not those on Medicare, Medicaid, TRICARE, or other government plans). Eligible patients may pay as little as $30 per 30-day prescription [1].

To activate the card in Delaware, patients visit the Takeda patient support website, complete an eligibility screening, and receive a digital or physical savings card. The card is presented at the pharmacy alongside the patient's insurance card. The savings card covers the difference between the patient's insurance copay and the $30 target, up to a specified annual maximum (typically $3,600 to $4,200 per calendar year, depending on the program year).

Key restrictions to know. The card cannot be combined with other manufacturer coupons. It does not apply if the patient's plan excludes Vyvanse entirely (the patient must have some level of insurance coverage for the card to function as a copay offset). Patients who reach the annual cap revert to their standard copay for the remainder of the year.

For uninsured patients in Delaware, Takeda operates the Takeda Help at Hand Patient Assistance Program, which provides brand Vyvanse at no cost to qualifying individuals whose household income falls below 250% of the federal poverty level [1]. Application requires documentation of income, residency, and a valid prescription.

Can You Get Vyvanse via Telehealth in Delaware?

Yes. Delaware permits telehealth prescribing of Schedule II controlled substances, including lisdexamfetamine, under both state and federal regulations [9]. The DEA's updated telehealth prescribing rules (finalized in late 2025) allow an initial Schedule II prescription via audio-video telehealth if the prescriber conducts an appropriate evaluation and the encounter is documented in the medical record [9].

Delaware-specific rules require that the telehealth prescriber hold an active Delaware medical license (or be practicing under a valid interstate compact agreement). The prescriber must use a HIPAA-compliant platform, and the patient must be physically located in Delaware at the time of the visit.

Several national telehealth platforms operate in Delaware and prescribe lisdexamfetamine, including services that specialize in ADHD evaluation and medication management. Costs for an initial ADHD telehealth evaluation in Delaware range from $150 to $300 without insurance; follow-up visits typically run $75 to $150. Some telehealth providers accept Delaware Medicaid managed care plans.

A 2023 study published in JAMA Network Open (N=1.2 million prescriptions) found that telehealth ADHD stimulant prescribing increased 3.2-fold between 2019 and 2022, with no corresponding increase in emergency department visits related to stimulant adverse effects [10]. The data suggest that telehealth-initiated stimulant therapy carries a safety profile comparable to in-person prescribing when standard evaluation protocols are followed.

Tips to Minimize Your Vyvanse Cost in Delaware

Start with the generic. Generic lisdexamfetamine is therapeutically equivalent to brand Vyvanse and costs a fraction of the price. Unless your prescriber has a documented clinical reason for brand-only, request the generic at the pharmacy counter [3].

Compare pharmacy prices. A 10-minute search across three or four Delaware pharmacies (including Costco, which does not require a membership for pharmacy services) can reveal price differences of $20 or more for the same generic medication. Use free pricing tools rather than relying solely on the first pharmacy you call.

Apply the Takeda savings card if you carry commercial insurance and your plan covers brand Vyvanse. Even a Tier 3 copay of $75 drops to $30 with the card active.

Ask about 503A compounding. If a licensed Delaware compounding pharmacy offers lisdexamfetamine at reduced cost, discuss this option with your prescriber. The compounded version may come in a different form (liquid suspension, for example) that some patients actually prefer.

Check patient assistance eligibility. Uninsured or underinsured patients earning below 250% FPL should apply to Takeda's Help at Hand program before paying cash prices [1].

The American Academy of Pediatrics recommends that cost should not be a barrier to evidence-based ADHD pharmacotherapy, and encourages prescribers to actively discuss affordability during every medication visit [11].